| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PHDG | -13.97% | $86.99M | 0.39% |
| DRSK | -13.62% | $1.27B | 0.78% |
| FMF | -13.30% | $163.26M | 0.95% |
| TESL | -12.10% | $32.83M | 1.2% |
| BNDX | -11.82% | $67.47B | 0.07% |
| FLIA | -11.08% | $705.51M | 0.25% |
| BWX | -11.02% | $1.52B | 0.35% |
| FXY | -10.84% | $793.88M | 0.4% |
| TAN | -9.24% | $678.29M | 0.71% |
| HYDR | -8.65% | $36.80M | 0.5% |
| TUR | -8.25% | $169.41M | 0.59% |
| SPSK | -8.20% | $332.37M | 0.5% |
| PPLT | -7.94% | $1.68B | 0.6% |
| IAGG | -7.81% | $10.52B | 0.07% |
| PTLC | -7.51% | $3.33B | 0.6% |
| BAB | -7.18% | $924.21M | 0.28% |
| YEAR | -7.06% | $1.47B | 0.25% |
| TAIL | -6.92% | $94.79M | 0.59% |
| VIXM | -6.70% | $23.12M | 0.85% |
| ICLN | -6.56% | $1.44B | 0.41% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BASE | 30.61% | $1.33B | +30.10% | 0.00% |
| GMS | 24.36% | $4.18B | +18.34% | 0.00% |
| VERV | 20.94% | $982.36M | +40.20% | 0.00% |
| KR | 20.66% | $47.52B | +34.10% | 1.78% |
| GXO | 19.71% | $5.89B | -7.74% | 0.00% |
| UAA | 19.66% | $2.91B | +2.40% | 0.00% |
| WLY | 19.48% | $2.18B | -15.56% | 3.46% |
| APT | 18.99% | $51.50M | -18.70% | 0.00% |
| UA | 18.48% | $2.72B | -2.59% | 0.00% |
| ORKA | 18.03% | $533.53M | -37.80% | 0.00% |
| ATEX | 17.49% | $440.85M | -44.10% | 0.00% |
| MSGS | 16.92% | $4.90B | +2.60% | 0.00% |
| BATRA | 16.69% | $3.07B | +6.13% | 0.00% |
| CRK | 16.31% | $6.77B | +120.73% | 0.00% |
| AMGN | 15.75% | $157.28B | -12.20% | 3.15% |
| CPSH | 15.08% | $35.88M | +40.74% | 0.00% |
| CACI | 15.03% | $10.44B | +7.18% | 0.00% |
| EIX | 14.99% | $19.40B | -31.79% | 6.44% |
| ZTS | 14.98% | $68.05B | -16.43% | 1.21% |
| WEN | 14.86% | $2.02B | -41.51% | 8.44% |
Yahoo
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Yahoo
Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE,
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DLS | -<0.01% | $1.01B | 0.58% |
| IVOL | 0.01% | $342.76M | 1.02% |
| USSG | 0.01% | $564.55M | 0.09% |
| DAPP | 0.02% | $243.82M | 0.51% |
| VXUS | 0.03% | $96.44B | 0.05% |
| AGG | 0.03% | $127.93B | 0.03% |
| HODL | -0.03% | $1.89B | 0.25% |
| KWEB | -0.04% | $6.36B | 0.7% |
| SATO | -0.04% | $11.77M | 0.6% |
| DISV | 0.04% | $3.28B | 0.42% |
| SOCL | -0.04% | $137.46M | 0.65% |
| SMDV | -0.04% | $667.74M | 0.4% |
| FBND | 0.05% | $19.32B | 0.36% |
| PIN | 0.05% | $233.44M | 0.78% |
| RIET | -0.06% | $90.69M | 0.5% |
| BND | 0.07% | $130.66B | 0.03% |
| BITO | 0.07% | $2.79B | 0.95% |
| FNCL | 0.07% | $2.27B | 0.084% |
| FDT | -0.08% | $540.87M | 0.8% |
| TYA | -0.08% | $147.83M | 0.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GRWG | -<0.01% | $58.66M | -61.63% | 0.00% |
| LBRDK | <0.01% | $12.57B | +63.94% | 0.00% |
| RGA | <0.01% | $12.71B | -10.10% | 1.85% |
| XPER | -<0.01% | $344.02M | -9.82% | 0.00% |
| SKX | 0.01% | $9.44B | -6.19% | 0.00% |
| GDOT | -0.01% | $585.68M | +6.81% | 0.00% |
| NSC | -0.01% | $58.50B | +10.52% | 2.07% |
| ELAN | 0.01% | $7.26B | +10.26% | 0.00% |
| TCBI | 0.02% | $3.90B | +20.17% | 0.00% |
| KBR | 0.02% | $5.91B | -32.66% | 1.38% |
| MTB | 0.02% | $31.67B | +20.94% | 2.72% |
| AUTL | 0.02% | $662.69M | -44.79% | 0.00% |
| PRAX | -0.02% | $1.06B | -2.32% | 0.00% |
| SDRL | 0.03% | $1.98B | -47.52% | 0.00% |
| LGIH | 0.03% | $1.19B | -52.61% | 0.00% |
| WAY | -0.04% | $6.57B | +69.28% | 0.00% |
| BIP | -0.04% | $14.92B | +2.47% | 5.17% |
| SCSC | 0.04% | $916.70M | -14.70% | 0.00% |
| EVER | -0.04% | $890.90M | +3.97% | 0.00% |
| SLVM | -0.04% | $2.04B | -30.58% | 3.58% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SWBI | -32.60% | $359.95M | -47.76% | 6.35% |
| CREG | -22.93% | $5.79M | -77.35% | 0.00% |
| SPTN | -15.92% | $897.34M | +38.80% | 3.30% |
| FI | -15.69% | $91.16B | +4.63% | 0.00% |
| JRVR | -15.40% | $265.72M | -31.64% | 1.39% |
| HCC | -15.37% | $2.65B | -30.09% | 0.63% |
| FIZZ | -15.15% | $4.21B | -13.19% | 0.00% |
| SKWD | -15.04% | $2.17B | +35.56% | 0.00% |
| CAPR | -14.75% | $327.95M | +48.24% | 0.00% |
| RUN | -13.94% | $2.45B | -38.05% | 0.00% |
| CMCO | -13.70% | $438.05M | -59.11% | 1.80% |
| INBK | -12.98% | $235.00M | -22.45% | 0.87% |
| TEO | -12.90% | $1.14B | +33.09% | 0.00% |
| SEDG | -12.38% | $1.62B | -9.37% | 0.00% |
| PSFE | -12.30% | $770.15M | -36.74% | 0.00% |
| EGBN | -11.90% | $638.53M | -6.95% | 4.46% |
| CBZ | -11.83% | $3.94B | -12.82% | 0.00% |
| PRPL | -11.67% | $69.95M | -56.03% | 0.00% |
| PLUG | -11.52% | $1.76B | -54.19% | 0.00% |
| CHDN | -11.47% | $7.53B | -27.75% | 0.39% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FLRN | 16.78% | $2.77B | 0.15% |
| FLTR | 16.47% | $2.44B | 0.14% |
| FLOT | 15.49% | $8.96B | 0.15% |
| CLOZ | 14.86% | $794.17M | 0.5% |
| DUSB | 14.49% | $1.37B | 0.15% |
| MINT | 14.13% | $13.34B | 0.35% |
| VUSB | 14.12% | $5.37B | 0.1% |
| HYEM | 14.11% | $401.88M | 0.4% |
| CLOI | 14.01% | $1.06B | 0.4% |
| HYBL | 13.75% | $427.62M | 0.7% |
| BSJQ | 13.31% | $1.06B | 0.42% |
| VRP | 12.53% | $2.14B | 0.5% |
| UNG | 12.48% | $422.40M | 1.06% |
| HYZD | 12.35% | $177.05M | 0.43% |
| FTSL | 12.35% | $2.40B | 0.87% |
| DBE | 12.27% | $54.90M | 0.77% |
| SHLD | 11.96% | $3.10B | 0.5% |
| ANGL | 11.85% | $2.93B | 0.25% |
| DBO | 11.51% | $233.44M | 0.77% |
| HYSA | 11.41% | $30.98M | 0.55% |
Current Value
$2.851 Year Return
Current Value
$2.851 Year Return
